Free Delivery on orders over £29*

Enurace Tablets for Dogs

Enurace Tablets for Dogs

  • 10mg » Priced per Tablet £0.29
  • 50mg » Priced per Tablet £0.29

Selection of 2 products from

£0.29

Description

Enurace Tablets are given to bitches which have been spayed (neutered or ovariohysterectomised). Enurace acts to tighten up the muscles near the exit to the bladder and is used to treat urinary incontinence.
It has been found that some spayed bitches start to leak urine when completely relaxed. This can start at any time after spaying, sometimes years later. Enurace tablets are normally given twice daily for life at the lowest effective dose.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

10mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

UK, NL, IT, BE, DE, ES: ENURACE 10, 10 mg tablets for dogs FR: ENURACE petit chien, comprimé

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance: 8.1 mg Ephedrine equivalent to 10 mg Ephedrine Hydrochloride.

Excipients: Ponceau 4R (E124) 0.08 mg

For a full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Tablets. Round, pink tablet with break line on one side and inscription ENURACE 10 on the other side.

  1. CLINICAL PARTICULARS

4.1 Target species Ovariohysterectomised female dogs.

4.2 Indications for use, specifying the target species Treatment of urinary incontinence caused by urethral sphincter mechanism incompetence in ovariohysterectomised female dogs.

4.3 Contraindications Do not use in dogs with glaucoma. Do not use in case of hypersensitivity to Ephedrine or to any of the excipients.

4.4 Special warnings for each target species This product is not suitable for treatment of inappropriate urination resulting of behaviour problems.

4.5 Special precautions for use

i. Special precautions for use in animals The safety and the efficacy of the product has not been assessed in dogs under 5 kg. Do not use the product in dogs under 5 kilogram of bodyweight.

As ephedrine is an alpha and beta adrenergic receptor agonist, the product should be used with caution in dogs with cardiovascular disease and only after a comprehensive risk/benefit analysis by the attending veterinarian.

The dog’s cardiovascular functionality should be carefully assessed before the start of the treatment with the product and it should be periodically monitored during the treatment.

In addition, a similar approach should be adopted in animals suffering from partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders. It should be mentioned that the Polyuria/Polydipsia (PU/PD) frequently accompanying the aforementioned conditions may be falsely diagnosed as urinary incontinence.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include insomnia and nervousness, dizziness, headache, increased blood pressure, increased sweating and nausea.

Ingestion may be fatal, especially in children. To avoid accidental ingestion, the product must be used and kept out of the reach of children. Always replace the cap securely after use.

In the event of accidental ingestion, most importantly by children, seek immediate medical attention showing the physician the package insert.

It is strongly recommended that pregnant women should wear gloves for administration.

Wash hands after administration.

4.6 Adverse reactions (frequency and seriousness) Cardiovascular effects like tachycardia, atrial fibrillation, stimulation of the heart activity; and vasoconstriction. Stimulation of the central nervous system leading to sleeplessness, excitation, anxiety and muscle tremors. Panting. Mydriasis. Cystitis. Bronchodilatation and decrease of mucus release in the respiratory mucosal membranes. Reduction of the motility and tone of the intestinal wall.

Due to the nature of Ephedrine the mentioned effects can occur at the recommended therapeutic dose, with anxiety and cardiovascular effects being the most prevalent. In 10% of the treatments, side effects have been observed in efficacy studies.

4.7 Use during pregnancy, lactation or lay Not applicable.

4.8 Interaction with other medicinal products and other forms of interaction Ephedrine may interact with other sympathicomimetics. Ephedrine may enhance glucocorticoid metabolism. Concomitant use with MAO-inhibitors may cause hypertension. Ephedrine can enhance the activity of products of the same class as theophylline. Volatile anaesthetics may enhance the sensitivity of the myocardium to the cardiovascular effects of Ephedrine. Concomitant use with cardiac glycosides, quinine and tricyclic antidepressants can cause arrhythmias. Vascular constrictions can occur after concomitant treatment with ergot alkaloids and oxytocin. Substances leading to an increase in pH of the urine are able to prolong the excretion of ephedrine, whereas substances leading to a decrease in pH of the urine are able to accelerate the excretion of ephedrine.

4.9 Amounts to be administered and administration route For oral administration only.

A starting dose of 2 mg Ephedrine HCl per kg of bodyweight per day, divided in two oral doses is recommended. Dogs can be dosed according to the following table:

Weight (kg) Dose (mg/day) Dose (Number of tablets) per day 1st gift 2nd gift 5 10 1 ½ ½ 7,5 15 1 ½ ½ 1 10 20 2 1 1 12,5 25 2 ½ 1 1 ½ 15 30 3 1 ½ 1 ½ 17,5 35 3 ½ 1 ½ 2 For weights superior or equal to 20 kg, use a higher strength of the product.

Desired therapeutic effect and occurrence of adverse effects have to be monitored approximately at 14 days, 1 month, 3 months and 6 months after the start. Based on the observed effect in comparison with the expected effect and taking into account the occurrence of adverse effects, the individual dose should be adjusted. The dose should be adjusted to find the lowest effective dose. Once the effective dose has been established, dogs should still be monitored at regular intervals, e.g. every six months.

The product should be administered before meals in a piece of food.

A maximum dose of 5 mg/ kg of bodyweight per day has to be respected.

4.10 Overdose (symptoms, emergency procedures, antidotes) The signs of overdose resemble those of the adverse reactions as described in section 4.6. In case of overdose, it is useful to accelerate excretion of ephedrine by acidification of the urine and enhanced diuresis.

4.11 Withdrawal period(s) Not applicable.

  1. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: symphaticomimetic ATCvet code: QG04BX90

5.1 Pharmacodynamic properties Ephedrine directly stimulates alpha- and beta-adrenergic receptors, present in all organ systems. It also stimulates the release of catecholamines from sympathic neurons. Since Ephedrine passes the blood-brain barrier, it also induces effects that are mediated through the central nervous system. Ephedrine specifically causes a contraction of the internal urethral sphincter muscles and a relaxation of the bladder muscles through a sympathicomimetic action on the adrenergic receptors.

5.2 Pharmacokinetic particulars Ephedrine is rapidly absorbed and the bioavailability is high. Ephedrine is widely distributed over the body. Degradation by demethylation to Norephedrine is the major metabolic pathway. Within 48 hours, urinary excretion accounts for elimination of 80 to 90 % of the administered dose, at high urinary acidity.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients Ponceau 4R (E124) Colloidal Silica Lactose Monohydrate Maize starch Magnesium Stearate

6.2 Incompatibilities None known.

6.3 Shelf life Shelf-life of the veterinary medicinal product as packaged for sale: 5 years.

6.4. Special precautions for storage Do not store above 25°C. Store in the original container. Divided tablets should be returned in the original package and used in the subsequent dose. Close the cap to the click.

6.5 Nature and composition of immediate packaging White polypropylene container containing 60 tablets with polyurethane cover-up and child-resistant closure system.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

Ecuphar NV Legeweg 157-i 8020 Oostkamp Belgium

  1. MARKETING AUTHORISATION NUMBER

Vm 32742/4001

  1. DATE OF FIRST AUTHORISATION

30 March 2010

  1. DATE OF REVISION OF THE TEXT

April 2012

PROHIBITION OF SALE, SUPPLY AND/OR USE

To be supplied only on veterinary prescription.

50mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

UK, NL, IT, BE, DE, ES: ENURACE 50, 50 mg tablets for dogs FR: ENURACE grand chien

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance: 40.7 mg Ephedrine equivalent to 50 mg Ephedrine Hydrochloride.

Excipients: For a full list of excipients, see section 6.1.

  1. PHARMACEUTICAL FORM

Tablets. Round, white tablet with break line on one side and inscription ENURACE 50 on the other side.

  1. CLINICAL PARTICULARS

4.1 Target species Ovariohysterectomised female dogs.

4.2 Indications for use, specifying the target species Treatment of urinary incontinence caused by urethral sphincter mechanism incompetence in ovariohysterectomised female dogs.

4.3 Contraindications Do not use in dogs with glaucoma. Do not use in case of hypersensitivity to Ephedrine or to any of the excipients.

4.4 Special warnings for each target species This product is not suitable for treatment of inappropriate urination resulting of behaviour problems.

4.5 Special precautions for use

i. Special precautions for use in animals Do not use the product in dogs under 20 kilogram of bodyweight.

As ephedrine is an alpha and beta adrenergic receptor agonist, the product should be used with caution in dogs with cardiovascular disease and only after a comprehensive risk/benefit analysis by the attending veterinarian.

The dog’s cardiovascular functionality should be carefully assessed before the start of the treatment with the product and it should be periodically monitored during the treatment.

In addition, a similar approach should be adopted in animals suffering from partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders. It should be mentioned that the Polyuria/Polydipsia (PU/PD) frequently accompanying the aforementioned conditions may be falsely diagnosed as urinary incontinence.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include insomnia and nervousness, dizziness, headache, increased blood pressure, increased sweating and nausea.

Ingestion may be fatal, especially in children. To avoid accidental ingestion, the product must be used and kept out of the reach of children. Always replace the cap securely after use.

In the event of accidental ingestion, most importantly by children, seek immediate medical attention showing the physician the package insert.

It is strongly recommended that pregnant women should wear gloves for administration.

Wash hands after administration.

4.6 Adverse reactions (frequency and seriousness) Cardiovascular effects like tachycardia, atrial fibrillation, stimulation of the heart activity; and vasoconstriction. Stimulation of the central nervous system leading to sleeplessness, excitation, anxiety and muscle tremors. Panting Mydriasis Cystitis Bronchodilatation and decrease of mucus release in the respiratory mucosal membranes. Reduction of the motility and tone of the intestinal wall.

Due to the nature of Ephedrine the mentioned effects can occur at the recommended therapeutic dose, with anxiety and cardiovascular effects being the most prevalent. In 10% of the treatments, side effects have been observed in efficacy studies.

4.7 Use during pregnancy, lactation or lay Not applicable.

4.8 Interaction with other medicinal products and other forms of interaction Ephedrine may interact with other sympathicomimetics. Ephedrine may enhance glucocorticoid metabolism. Concomitant use with MAO-inhibitors may cause hypertension. Ephedrine can enhance the activity of products of the same class as theophylline. Volatile anaesthetics may enhance the sensitivity of the myocardium to the cardiovascular effects of Ephedrine. Concomitant use with cardiac glycosides, quinine and tricyclic antidepressants can cause arrhythmias. Vascular constrictions can occur after concomitant treatment with ergot alkaloids and oxytocin. Substances leading to an increase in pH of the urine are able to prolong the excretion of ephedrine, whereas substances leading to a decrease in pH of the urine are able to accelerate the excretion of ephedrine.

4.9 Amounts to be administered and administration route For oral administration only.

A starting dose of 2 mg Ephedrine HCl per kg of bodyweight per day, divided in two oral doses is recommended. Dogs can be dosed according to the following table:

Weight (kg) Dose (mg/day) Dose (Number of tablets) per day 1st gift 2nd gift 20-30 50 1 ½ ½ 31-40 75 1 ½ ½ 1 41-50 100 2 1 1

Desired therapeutic effect and occurrence of adverse effects have to be monitored approximately at 14 days, 1 month, 3 months and 6 months after the start. Based on the observed effect in comparison with the expected effect and taking into account the occurrence of adverse effects, the individual dose should be adjusted. The dose should be adjusted to find the lowest effective dose. Once the effective dose has been established, dogs should still be monitored at regular intervals, e.g. every six months.

The product should be administered before meals in a piece of food.

A maximum dose of 5 mg/ kg of bodyweight per day has to be respected.

4.10 Overdose (symptoms, emergency procedures, antidotes) The signs of overdose resemble those of the adverse reactions as described in section 4.6. In case of overdose, it is useful to accelerate excretion of ephedrine by acidification of the urine and enhanced diuresis.

4.11 Withdrawal period(s) Not applicable.

  1. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: symphaticomimetic ATCvet code: QG04BX90

5.1 Pharmacodynamic properties Ephedrine directly stimulates alpha- and beta-adrenergic receptors, present in all organ systems. It also stimulates the release of catecholamines from sympathic neurons. Since Ephedrine passes the blood-brain barrier, it also induces effects that are mediated through the central nervous system. Ephedrine specifically causes a contraction of the internal urethral sphincter muscles and a relaxation of the bladder muscles through a sympathicomimetic action on the adrenergic receptors.

5.2 Pharmacokinetic particulars Ephedrine is rapidly absorbed and the bioavailability is high. Ephedrine is widely distributed over the body. Degradation by demethylation to Norephedrine is the major metabolic pathway. Within 48 hours, urinary excretion accounts for elimination of 80 to 90 % of the administered dose, at high urinary acidity.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients Colloidal Silica Lactose Monohydrate Microcrystalline Cellulose Magnesium Stearate

6.2 Incompatibilities None known.

6.3 Shelf life Shelf-life of the veterinary medicinal product as packaged for sale: 5 years.

6.4. Special precautions for storage Do not store above 25°C. Store in the original container. Divided tablets should be returned in the original package and used in the subsequent dose. Close the cap to the click.

6.5 Nature and composition of immediate packaging White LDPE container containing 100 tablets with polyurethane cover-up and cap with a child-resistant closure.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

  1. MARKETING AUTHORISATION HOLDER

    Ecuphar NV Legeweg 157-I 8020 Oostkamp Belgium T + 32 (0) 50 31 45 10 F + 32 (0) 50 36 28 00

  2. MARKETING AUTHORISATION NUMBER

    Vm 32742/4002

  3. DATE OF FIRST AUTHORISATION

4 January 2008

  1. DATE OF REVISION OF THE TEXT

October 2011

PROHIBITION OF SALE, SUPPLY AND/OR USE

To be supplied only on veterinary prescription.

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (6)

Q & A

There are currently no questions for Enurace Tablets for Dogs - be the first to ask one!